Kolexia
Dreyer Chantal Oncologie médicale
Dreyer Chantal
Oncologie médicale
Gh Paris Site Saint Joseph
Paris, France
105 Activités
255 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Carcinomes Carcinome hépatocellulaire Cholangiocarcinome Tumeurs neuroendocrines Tumeurs du foie Douleur nociceptive Tumeurs du pancréas Carcinome épidermoïde Tumeurs colorectales

Collaborateurs

Voir plus
Raymond Eric
Raymond Eric
Gh Paris Site Saint Joseph, Paris, France
Faivre Sandrine
Faivre Sandrine
Hôpital Beaujon, Clichy, France
Bouattour Mohamed
Bouattour Mohamed
Hôpital Beaujon, Clichy, France
Hentic-Dhome Olivia
Hentic-Dhome Olivia
Hôpital Beaujon, Clichy, France

Industries

Voir plus
MARIE AMELIE LENOIR CONSULTING - VICTA CONSEIL
2 collaboration(s)
Dernière en 2020
Pfizer
2 collaboration(s)
Dernière en 2022
Ipsen
1 collaboration(s)
Dernière en 2021
Novartis
1 collaboration(s)
Dernière en 2021

Dernières activités

Voir plus
Targeting the Tumor Microenvironment through mTOR Inhibition and Chemotherapy as Induction Therapy for Locally Advanced Head and Neck Squamous Cell Carcinoma: The CAPRA Study.
Cancers   17 septembre 2022
Study of GNS561 in Patients With Liver Cancer: Phase 1/2a Study to Evaluate the Safety, Activity, and Pharmacokinetics of Escalating Doses of GNS561 in Patients With Primary and Secondary Liver Cancer
Essai Clinique (Genoscience Pharma)   25 avril 2022
First-In-Human Effects of PPT1 Inhibition Using the Oral Treatment with GNS561/Ezurpimtrostat in Patients with Primary and Secondary Liver Cancers.
Liver cancer   15 février 2022
First-in-human phase I, pharmacokinetic (PK), and pharmacodynamic (PD) study of oral GNS561, a palmitoyl-protein thioesterase 1 (PPT1) inhibitor, in patients with primary and secondary liver malignancies.
2021 ASCO Annual Meeting I   28 mai 2021
Octobre rose : Les soins de support
Youtube @ Hôpitaux Saint-Joseph Marie-Lannelongue   13 novembre 2020
Preliminary safety and pharmacokinetics of a new lysosomotropic oral agent, GNS561, in a first-in-human study in advanced primary liver cancer patients
Abstract Book of the 44th ESMO Congress (ESMO 2019) 27 September – 1 October 2019, Barcelona, Spain   01 octobre 2019
Clinical and Biomarker Evaluations of Sunitinib in Patients with Grade 3 Digestive Neuroendocrine Neoplasms.
Neuroendocrinology   08 mars 2018
BRAF-Mutated Colorectal Cancer: What Is the Optimal Strategy for Treatment?
Current treatment options in oncology   10 août 2017
SUN-CK: A Phase II Open-label Single Arm Study of Sunitinib in Patients With Advanced Cholangiocarcinoma
Essai Clinique (GERCOR (Multidisciplinary Group in Oncology))   30 janvier 2017
Pharmacokinetics and safety of DTS-108, a human oligopeptide bound to SN-38 with an esterase-sensitive cross-linker in patients with advanced malignancies: a Phase I study.
International journal of nanomedicine   21 novembre 2016